Pharmaceutical Preparations · DE · CIK 1595097
Corbus Pharmaceuticals develops new therapies for oncology and obesity
Comparable business profile · signals at a glance
In the 90 days to Mar 2, 2026: 5 sold $592K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Smethurst DominicChief Medical Officer | Sell | 6,097 | $8.30 | $51K |
| Feb 17, 2026 | Hodgson IanChief Operating Officer | Sell | 847 | $7.38 | $6K |
| Feb 13, 2026 | Cohen YuvalChief Executive Officer | Sell | 13,871 | $7.78 | $108K |
| Feb 13, 2026 | Moran Sean F.Chief Financial Officer | Sell | 4,701 | $7.78 | $37K |
| Feb 3, 2026 | Smethurst DominicChief Medical Officer | Sell | 3,285 | $8.09 | $27K |
| Feb 3, 2026 | Hodgson IanChief Operating Officer | Sell | 2,415 | $8.09 | $20K |
| Dec 11, 2025 | Chen BihuaTenPercentOwner | Sell | 30,029 | $11.46 | $344K |
| Oct 27, 2025 | Cohen YuvalChief Executive Officer | Sell | 8,973 | $17.14 | $154K |
| Oct 24, 2025 | Cohen YuvalChief Executive Officer | Sell | 18,660 | $17.01 | $317K |
| Oct 24, 2025 | Moran Sean F.Chief Financial Officer | Sell | 12,981 | $17.02 | $221K |
| Oct 20, 2025 | Altmeyer AnneDirector | Sell | 1,060 | $20.50 | $22K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 14 reputable articles.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗